Skip to main content
SpringerLink
Log in

Glycated proteins and cardiovascular disease in glucose intolerance and type 2 diabetes

  • Published:
Current Cardiovascular Risk Reports Aims and scope Submit manuscript

Abstract

Individuals with diabetes have more atherosclerosis and cardiovascular events and a higher complication rate from cardiovascular events than nondiabetic individuals. Also, lesions from diabetic patients are more prone to rupture and exhibit more intravascular thrombosis than those from nondiabetic patients. Glucose modification of circulating proteins and matrix proteins mediates the activation of the inflammatory pathways critical in diabetes-associated atherosclerosis. Extracellular matrix proteins containing advanced glycation end products (AGEs) serve as ligands for scavenger receptors and the receptor for AGEs. Ligation of the receptor for AGEs activates inflammatory pathways and destabilizes atherosclerotic plaques in diabetic patients. Clinically, researchers have used concentrations of fructosamine and glycosylated hemoglobin to investigate the relationships among glycemia, glucose-modified proteins, and cardiovascular risk. They found that increased levels of fructosamine and hemoglobin A1c are associated with a significantly increased multivariable-adjusted risk of cardiovascular events.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Sprafka JM, Burke GL, Folsom AR, et al.: Trends in prevalence of diabetes mellitus in patients with myocardial infarction and effect of diabetes on survival. The Minnesota Heart Survey. Diabetes Care 1991, 14:537–543.

    Article  PubMed  CAS  Google Scholar 

  2. Miettinen H, Lehto S, Salomaa V, et al.: Impact of diabetes on mortality after the first myocardial infarction. The FINMONICA Myocardial Infarction Register Study Group. Diabetes Care 1998, 21:69–75.

    Article  PubMed  CAS  Google Scholar 

  3. Haffner SM, Lehto S, Ronnemaa T, et al.: Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998, 339:229–234.

    Article  PubMed  CAS  Google Scholar 

  4. Rosenson, RS: The atherosclerotic milieu of diabetes. In Diabetes Management for Cardiologists. Edited by Brown AS. New York: Professional Publishing Group; In press.

  5. Brizzi MF, Dentelli P, Pavan M, et al.: Diabetic LDL inhibits cell-cycle progression via STAT5B and p21(waf). J Clin Invest 2002, 109:111–119.

    Article  PubMed  CAS  Google Scholar 

  6. Morgan DO: Principles of CDK regulation. Nature 1995, 374:131–134.

    Article  PubMed  CAS  Google Scholar 

  7. van Brussel BL, Plokker HW, Voors AA, et al.: Multivariate risk factor analysis of clinical outcome 15 years after venous coronary artery bypass graft surgery. Eur Heart J 1995, 16:1200–1206.

    PubMed  Google Scholar 

  8. Takazawa K, Hosoda Y, Yamamoto T, et al.: Coronary artery bypass grafting. Late result of actual 10-years follow-up in 376 patients. Jpn J Thorac Cardiovasc Surg 1999, 47:110–115.

    PubMed  CAS  Google Scholar 

  9. Nishikawa T, Edelstein D, Du XL, et al.: Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 2000, 404:787–790.

    Article  PubMed  CAS  Google Scholar 

  10. Basta G. Lazzerini G, Massaro M, et al.: Advanced glycation end products activate endothelium through signal-transduction receptor RAGE: a mechanism for amplification of inflammatory responses. Circulation 2002, 105:816–822.

    Article  PubMed  CAS  Google Scholar 

  11. Masashi F, Hiroko O, Osamu T, et al.: Blockade of angiotensin II receptors reduces the expression of receptors for advanced glycation end products in human endothelial cells. Arterioscler Thromb Vasc Biol 2006, 26:e138–e142.

    Article  CAS  Google Scholar 

  12. Cipollone F, Iezzi A, Fazia M, et al.: The receptor RAGE as a progression factor amplifying arachidonate-dependent inflammatory and proteolytic response in human atherosclerotic plaques: role of glycemic control. Circulation 2003, 108:1070–1077.

    Article  PubMed  CAS  Google Scholar 

  13. Browner WS, Pressman AR, Lui LY, Cummings SR: Association between serum fructosamine and mortality in elderly women: the study of osteoporotic fractures. Am J Epidemiol 1999, 149:471–475.

    PubMed  CAS  Google Scholar 

  14. Nathan DM, Singer DE, Hurxthal K, Goodson JD: The clinical information value of the glycosylated hemoglobin assay. N Engl J Med 1984, 310:341–346.

    Article  PubMed  CAS  Google Scholar 

  15. Goldstein DE, Little RR, Wiedmeyer HM, et al.: Glycated hemoglobin: methodologies and clinical applications. Clin Chem 1986, 32B:64–70.

    Google Scholar 

  16. Klein R: Hyperglycemia and microvascular and macrovascular disease in diabetes. Diabetes Care 1995, 18:258–268.

    Article  PubMed  CAS  Google Scholar 

  17. Adler AI, Neil AW, Manley SE, et al.: Hyperglycemia and hyperinsulinemia at diagnosis of diabetes and their association with subsequent cardiovascular disease in the United Kingdom Prospective Diabetes Study (UKPDS 47). Am Heart J 1999, 138:S353–S359.

    PubMed  CAS  Google Scholar 

  18. Stratton IM, Adler AI, Neil HA, et al.: Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UPKDS 35): prospective observational study. BMJ 2000, 321:405–412.

    Article  PubMed  CAS  Google Scholar 

  19. Stevens RJ, Coleman RL, Adler AI, et al.: Risk factors for myocardial infarction case fatality and stroke case fatality in type 2 diabetes: UKPDS 66. Diabetes Care 2004, 27:201–207.

    Article  PubMed  Google Scholar 

  20. Seltzer HS: A summary of criticisms of the findings and conclusions of the University Group Diabetic Program (UGDP). Diabetes 1972, 21:976–979.

    PubMed  CAS  Google Scholar 

  21. Ohkubo Y, Kishikawa H, Araki E, et al.: Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995, 28:103–117.

    Article  PubMed  CAS  Google Scholar 

  22. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998, 352:837–853.

  23. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998, 352:854–865.

Download references

Author information

Authors and Affiliations

  1. Preventive Cardiology Center, University of Michigan School of Medicine, 24 Frank Lloyd Wright Drive-Lobby A, Third Floor, Ann Arbor, MI, 48106, USA

    Robert S. Rosenson

Authors
  1. Robert S. Rosenson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. William H. Herman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Robert S. Rosenson.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rosenson, R.S., Herman, W.H. Glycated proteins and cardiovascular disease in glucose intolerance and type 2 diabetes. Curr Cardio Risk Rep 2, 43–46 (2008). https://doi.org/10.1007/s12170-008-0009-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12170-008-0009-0

Keywords

Search

Navigation